eyeforpharma
About Us   Contact Us
 
 
Follow Me
Twitter
Linked In
Global Sponsors
Gold Sponsors
Supporting Sponsors
 
 
 
 
 
Register Now
Attendees Included

Abbott
Adamed
AMAG Pharmaceuticals
Astellas
AstraZeneca
Aton Pharma
Bayer
Biogen Idec
BMS
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene Corporation
Cipher Pharmaceuticals
Cubist Pharmaceuticals
CVS Caremark
Daiichi Sankyo
Dyax Corp
Eidetics
Eisai Inc.
Eli Lilly & Company
ETHICON, Inc., a Johnson & Johnson company
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Ironwood Pharmaceuticals
Johnson & Johnson
Lab Stein
MedImmune
Merck & Co, Inc.
Millennium Pharmaceuticals
Novartis
Noven Pharmaceuticals
Novo Nordisk
Pfizer
Purdue Pharma
sanofi-aventis
Sepracor
Solvay Pharmaceuticals
Stiefel, a GSK Company
Synovate Healthcare
Tabros Pharma
Teva Pharmaceuticals
Themis Analytics
Vertex Pharmaceuticals

Quotes
22-23 October, Berlin

Missed the event? Get the video presentations straight to your inbox

This year's speakers

Several key themes and debates about change and customer-centricity emerged at this year’s eyeforpharma 9th annual Pharma Marketing Summit 2009 conference in Berlin, October 22-23rd.


Making the customer the center of gravity


“The customer is the ‘center of gravity’ Armin Pearn, business innovation director at Pfizer AH and a speaker at the event stated. Jane Griffiths of Janssen-Cilag agrees. “Trustful, intelligent communications will help build partnerships and open new dialogs,” she says. But Jo Jarvis, head of advocacy at Wyeth, stresses that marketers must know who they want to build relationships with and do their homework before they meet.


Market access – the fourth hurdle


Nowhere is responding to change more critical than when it comes to market access strategies. Getting regulatory agency approval for a new drug was once the end goal of drug development but in today’s healthcare environment, where governments increasingly determine price and availability of drugs, market access has become the ‘fourth hurdle’ in successfully bringing a drug to market.


“There’s an opportunity, I believe, to engage earlier with organizations like NICE in the UK to see what kind of endpoints would be useful to develop in phase III to allow them to appraise new drugs a bit more easily,” Rajesh Gupta, Former VP Merck Serona says.


To continue the debate and discover the key learnings click here to purchase the video recording